IAM
ADVM

Integre Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

Integre Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,548
Closed -$45K – 117
2016
Q4 		$45K Hold
1,548
– – 0.01% 130
2016
Q3 		$64K Buy
+1,548
New +$58.7K 0.02% 129

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Integre Asset Management's ADVM Position: Q1 2017 in Review

Integre Asset Management sold out of Adverum Biotechnologies (ADVM) in Q1 2017, closing a stake of 1,548 shares — an estimated $45K sold.

Integre Asset Management first reported a position in ADVM in Q3 2016 and held it in 2 quarters. The position peaked at $64K in Q3 2016. 75 funds tracked by Wall St. Rank hold ADVM as of Q1 2017.

  • Integre Asset Management reported no remaining Adverum Biotechnologies position as of Q1 2017 after selling out during the quarter.
  • Integre Asset Management sold 1,548 Adverum Biotechnologies shares in Q1 2017, an estimated $45K.
  • Integre Asset Management first reported a position in Adverum Biotechnologies in Q3 2016 and held it in 2 quarters.
  • Integre Asset Management's Adverum Biotechnologies position peaked at $64K in Q3 2016.
  • 75 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2017.

Based on Integre Asset Management's 13F filing for Q1 2017, filed 15 May 2017.